Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Guidant CrossSail

This article was originally published in The Gray Sheet

Executive Summary

Rapid-exchange coronary dilatation catheter and OpenSail over-the-wire counterpart gain FDA market go-ahead for use in native coronary vessels and saphenous vein grafts. The angioplasty devices offer "the smallest profiles of any coronary dilatation catheter currently available," Guidant claims, and "incorporate significant technological advancements." Launched earlier this year in CE mark countries, CrossSail's U.S. debut is set for early July, while the OpenSail will be introduced "upon completion of the CrossSail launch," Guidant says. The devices feature a SofTech tip with a "soft, tapered-tip shape," LoFold balloon folding technology, Xcelon S nylon-blend balloon material and Hydrocoat hydrophilic coating
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT013566

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel